petosemtamab
merus
['mcla-158', 'petosemtamab']
very proud of our contribution to the development of petosemtamab/mcla-158 looking forward to the results from the clinical trial #aacr2023 
We work on residual disease and metastasis by colorectal cancer from the perspective of cancer stem cells and their interaction with the tumor microenvironment.